Physician profile
Usha G Thalody
NPI 1740472885
$6,289.07
in general payments reported to CMS, 2019-2025
31 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $855 · 2021: $661 · 2022: $1,103 · 2023: $887 · 2024: $881 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,846.08 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Astrazeneca Pharmaceuticals Lp | $1,059.84 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $498.70 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.33 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $343.47 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $266.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $252.49 | 2019 | |
| Optinose US, INC. | $204.12 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $146.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $137.11 | 2019-2023 | Steglatro, Belsomra |
| Lilly USA, LLC | $128.25 | 2019-2024 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $95.88 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $81.77 | 2022-2024 | |
| Abbott Laboratories | $76.96 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $74.22 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.04 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.73 | 2019 | |
| Astellas Pharma US INC | $59.30 | 2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $57.26 | 2021-2022 | |
| Allergan, INC. | $56.65 | 2019-2020 | |
| Amgen INC. | $53.85 | 2019-2020 | |
| Abbvie INC. | $53.66 | 2021-2023 | Ubrelvy |
| Exact Sciences Corporation | $43.20 | 2024-2025 | Cologuard Collection Kit |
| Mannkind Corporation | $42.41 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $41.59 | 2021-2022 | |
| Pfizer INC. | $19.95 | 2023 | |
| Mylan Specialty L.P. | $19.47 | 2020 | |
| Dexcom, INC. | $17.24 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $16.16 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.00 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Thalody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.